206 related articles for article (PubMed ID: 32497977)
21. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.
Lefever TW; Marusich JA; Antonazzo KR; Wiley JL
Pharmacol Biochem Behav; 2014 Mar; 118():30-5. PubMed ID: 24412835
[TBL] [Abstract][Full Text] [Related]
22. Random-ratio schedules produce greater demand for i.v. drug administration than fixed-ratio schedules in rhesus monkeys.
Lagorio CH; Winger G
Psychopharmacology (Berl); 2014 Aug; 231(15):2981-8. PubMed ID: 24562063
[TBL] [Abstract][Full Text] [Related]
23. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.
Yuill MB; Hale DE; Guindon J; Morgan DJ
Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802
[TBL] [Abstract][Full Text] [Related]
24. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
25. Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys.
Li JX; Koek W; France CP
Behav Pharmacol; 2012 Dec; 23(8):754-61. PubMed ID: 23044830
[TBL] [Abstract][Full Text] [Related]
26. Effects of daily morphine administration and deprivation on choice and demand for remifentanil and cocaine in rhesus monkeys.
Wade-Galuska T; Galuska CM; Winger G
J Exp Anal Behav; 2011 Jan; 95(1):75-89. PubMed ID: 21541117
[TBL] [Abstract][Full Text] [Related]
27. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Negus SS; Schrode K; Stevenson GW
Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
[TBL] [Abstract][Full Text] [Related]
28. Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence.
Barbieri M; Ossato A; Canazza I; Trapella C; Borelli AC; Beggiato S; Rimondo C; Serpelloni G; Ferraro L; Marti M
Neuropharmacology; 2016 Oct; 109():254-269. PubMed ID: 27346209
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.
Solinas M; Panlilio LV; Tanda G; Makriyannis A; Matthews SA; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2046-57. PubMed ID: 15870833
[TBL] [Abstract][Full Text] [Related]
30. Delay discounting of the μ-opioid receptor agonist remifentanil in rhesus monkeys.
Maguire DR; Gerak LR; France CP
Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):148-54. PubMed ID: 26397761
[TBL] [Abstract][Full Text] [Related]
31. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
Maguire DR; France CP
Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
[TBL] [Abstract][Full Text] [Related]
32. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
De Luca MA; Castelli MP; Loi B; Porcu A; Martorelli M; Miliano C; Kellett K; Davidson C; Stair JL; Schifano F; Di Chiara G
Neuropharmacology; 2016 Jun; 105():630-638. PubMed ID: 26686391
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice.
Yu Y; Tsang QK; Jaramillo-Polanco J; Lomax AE; Vanner SJ; Reed DE
J Neurosci; 2022 Aug; 42(33):6313-6324. PubMed ID: 35790401
[TBL] [Abstract][Full Text] [Related]
34. Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys.
Minervini V; France CP
Behav Pharmacol; 2018 Feb; 29(1):60-70. PubMed ID: 28952976
[TBL] [Abstract][Full Text] [Related]
35. JWH-018 impairs sensorimotor functions in mice.
Ossato A; Vigolo A; Trapella C; Seri C; Rimondo C; Serpelloni G; Marti M
Neuroscience; 2015 Aug; 300():174-88. PubMed ID: 25987201
[TBL] [Abstract][Full Text] [Related]
36. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
Hopkins CY; Gilchrist BL
J Emerg Med; 2013 Oct; 45(4):544-6. PubMed ID: 23890687
[TBL] [Abstract][Full Text] [Related]
37. Self-administration of cocaine and remifentanil by monkeys: choice between single drugs and mixtures.
Freeman KB; Woolverton WL
Psychopharmacology (Berl); 2011 May; 215(2):281-90. PubMed ID: 21191570
[TBL] [Abstract][Full Text] [Related]
38. Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys.
John WS; Martin TJ; Nader MA
Neuropsychopharmacology; 2017 Jun; 42(7):1522-1530. PubMed ID: 28059083
[TBL] [Abstract][Full Text] [Related]
39. Adolescent Cannabinoid and Nicotine Exposure Differentially Alters Adult Nicotine Self-Administration in Males and Females.
Dukes AJ; Fowler JP; Lallai V; Pushkin AN; Fowler CD
Nicotine Tob Res; 2020 Jul; 22(8):1364-1373. PubMed ID: 32396625
[TBL] [Abstract][Full Text] [Related]
40. Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.
Gerak LR; Zanettini C; Koek W; France CP
Psychopharmacology (Berl); 2015 Oct; 232(19):3637-47. PubMed ID: 26202613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
